Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Apotex, Biocon, Dizal, Johnson & Johnson, OS Therapies, Regeneron.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 4DMT, Alera, Boehringer Ingelheim, CB, Clinigen, Maat, Neurizon, Oxford, Theratechnologies.
Biopharma companies raised $7.38 billion across 99 transactions in June 2025, up from $5.55 billion in May and $2.4 billion in April. For the first half of the year (H1), total financings reached $28.74 billion, down 59% from the $70.32 billion raised during the same period in 2024. Although lower than the record-setting levels of 2020 and 2021, the current total aligns more closely with recent years, including $26.57 billion in the first half of 2022 and $30.57 billion in 2023.
RSS
